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Abstract
Background: Human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) is an
aggressive form of breast cancer and is historically associated with poor outcomes compared with HER2-negative
MBC. Since 1998, four drugs have been globally approved for the targeted treatment of HER2-positive MBC.
Additional advances in patient care—such as improved breast cancer screening, HER2 testing, and supportive
care—have also occurred. The objective of this systematic review and meta-analysis is to determine whether there
has been a cumulative change in survival over time in patients with HER2-positive advanced breast cancer based
on results from interventional clinical trials (ICTs) and observational studies and to compare outcomes across these
types of studies.
Methods/Design: A systematic search of Medline, EMBASE, and the Cochrane Central Register of Controlled Trials
will be performed. Two investigators will independently assess each abstract for inclusion. English language reports
of ICTs and observational studies that include patients with HER2-positive advanced breast cancer from 1987
onwards will be considered. The primary outcome of interest is overall survival; secondary outcomes include
progression-free survival and safety. Data on clinical outcomes, as well as on study design, study population,
treatment/intervention, methodological quality, and outcomes, will be extracted using a structured codebook
developed by the authors for this study. Standard and cumulative random effects meta-analysis will be performed
to derive pooled risk estimates, both overall and by study design, controlling for covariates such as aggregate
demographic and clinical characteristics of patients, treatment/intervention, and study characteristics. Heterogeneity
of studies will be evaluated using the I2 statistic. Differences in risk estimates by quality characteristics will be
performed using meta-regression.
Discussion: This study will evaluate current and evolving trends in survival associated with HER2-positive advanced
breast cancer over nearly 30 years and will build upon prior, less comprehensive, systematic analyses. This
information is important to patients, healthcare providers, and researchers, particularly in the advanced disease
setting, in which new therapies have been recently approved. Including observational studies allows us to evaluate
real-world effectiveness; useful information will be gained by comparing findings from observational studies with
those from ICTs.
Systematic review registration: PROSPERO CRD42014014345
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Background
Breast cancer is the most common cancer among
women worldwide. Globally, there were an estimated
1.67 million new breast cancer diagnoses and 522,000
breast cancer-related deaths in 2012 [1]. Human epider-
mal growth factor receptor 2 (HER2) is overexpressed in
15–20 % of all primary breast tumors [2–4]. Overexpres-
sion of HER2 is associated with indicators of more ag-
gressive disease, such as positive lymph nodes and high
nuclear grade [5–8]. Consistent with this, prior to the
availability of HER2-targeted therapy, patients with
HER2-positive breast cancer experienced significantly
shorter disease-free survival [5, 6, 9] and an approxi-
mately twofold increase in breast cancer mortality [10–
12] relative to patients with HER2-normal breast cancer.
The first HER2-targeted therapy, the humanized
monoclonal antibody trastuzumab, was approved for the
treatment of patients with metastatic breast cancer
(MBC) in 1998. Since then, three additional HER2-
targeted agents have been approved: the tyrosine kinase
inhibitor lapatinib, the humanized monoclonal antibody
pertuzumab, and the antibody–drug conjugate trastuzu-
mab emtansine (T-DM1). In addition to these therapies,
other advances in the care of patients identified with
HER2-positive advanced breast cancer (i.e., MBC or lo-
cally advanced breast cancer [LABC]) have occurred,
such as improvements in breast cancer screening, ad-
vances in reliable identification of HER2-positive disease,
refinement of interventional approaches, and improve-
ments in supportive care.
In the most comprehensive systematic review of
HER2-targeted therapy to date, Giordano and colleagues
evaluated all comparative phase III randomized trials,
systematic reviews, and meta-analyses of patients with
HER2-positive advanced breast cancer published
through October 2012 [13]. The analysis found that
HER2-targeted regimens were associated with improve-
ments in both progression-free survival (PFS) and overall
survival (OS) relative to chemotherapy alone. This ana-
lysis, however, did not evaluate potential changes in the
magnitude of the improvements in PFS and OS over
time but focused, instead, on the collective impact of
HER2-targeted therapies. While a different systematic
review did set out to define changes observed in ran-
domized clinical trials in survival over time, including in
studies of patients with HER2-positive advanced breast
cancer, this systematic review included only studies that
assessed trastuzumab-based therapy [14]. With multiple
HER2-targeted treatments now available, there is a need
to analyze all available data in a comprehensive way.
While no comprehensive systematic reviews of poten-
tial changes in outcomes with HER2-targeted therapy
over time in randomized clinical trials are currently
available, data from historical versus current phase III
randomized clinical trials suggest that survival outcomes
may be changing. For example, from June 1995 to
March 1997, the phase III trial that supported the licen-
sure of trastuzumab recruited patients with HER2-
positive MBC (including patients with both HER2 im-
munohistochemistry (IHC) 3+ and IHC 2+ tumors) who
were not previously treated in the metastatic setting.
Median OS among patients who received trastuzumab
plus chemotherapy was 25.1 months compared with
20.3 months in the control arm [15]. Recruitment for
the phase III CLEOPATRA study occurred between Feb-
ruary 2008 and July 2010 [16]. The study included pa-
tients with HER2-positive advanced breast cancer (IHC
3+ or amplification ratio ≥2.0 by fluorescence in situ
hybridization) not previously treated in the metastatic
setting. Median OS was 40.8 months in the control arm
(trastuzumab plus docetaxel) and 56.5 months in the
pertuzumab arm (pertuzumab plus trastuzumab plus do-
cetaxel) [17]. This comparison across clinical trials, how-
ever, is limited because of differences in study designs
and patient populations. A comprehensive review and
assessment of published interventional clinical trials is
necessary to determine if a reliable change in outcomes
exists.
Further, data from clinical trials do not always reflect
findings in real-world clinical populations. To reduce po-
tential biases in randomized clinical trials and other inter-
ventional trials, inclusion and exclusion criteria are
applied. This can result in patient populations that are not
universally generalizable to the routine clinical practice
setting in which patients may have substantial differences
in demographic characteristics, more comorbidities and
concomitant medications, as well as complex psychosocial
circumstances. In addition, patients enrolled in clinical tri-
als tend to be higher functioning [18], and treatments/in-
terventions and assessments are more uniform and more
closely monitored. Observational studies may more closely
approximate clinical practice in that these studies tend to
have fewer inclusion criteria and less stringent assessment
schedules. However, since treatments and assessments are
generally less uniformly applied, data on treatment/inter-
vention effects may be more variable. Further, observa-
tional studies may be more subject to certain types of
biases, such as selection bias due to the absence of
randomization [19].
There are limited published data on the collective ef-
fect of interventions to manage HER2-positive ad-
vanced breast cancer on outcomes in patients in real-
world settings, and none of these systematically assess
changes in survival outcomes over time. New data from
a large epidemiological database of the California popu-
lation, the California Cancer Registry, suggest that
current survival outcomes for patients with HER2-
positive MBC are similar to current survival outcomes
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for patients with HER2-negative MBC. This study,
which included 6268 patients with MBC and 118,817
patients with early-stage breast cancer, found 3-year
survival rates of 47.6 % for patients with HER2-positive
MBC and 44.8 % for patients with HER2-negative MBC
[20]. These similar 3-year survival rates stand in con-
trast with the negative prognosis associated with HER2-
positive breast cancer that existed prior to the availabil-
ity of HER2-directed therapy [5, 6, 9–12]. However, it
cannot be concluded that the similar 3-year survival
rates are due to HER2-directed therapy since observa-
tional studies can only show associations, rather than
direct causes and effects. While these data suggest
changes in real-world survival outcomes over time, it is
necessary to comprehensively review and assess pub-
lished observational studies to examine whether such a
change has occurred.
Thus, limited evidence from both observational and
randomized clinical trial data—as well as clinical experien-
ce—suggests that patients with HER2-positive advanced
breast cancer have experienced improved survival out-
comes over time. However, to our knowledge, no prior re-
search has examined this by systematically assessing
available phase II and III interventional clinical trial and
observational study data, regardless of treatment/interven-
tion, over a 30-year period. It is particularly important to
assess the clinical implications of data from interventional
clinical trials by investigating similar outcomes in the real-
world setting, in which patients may have concomitant
disease and more negative prognostic factors than those
in interventional clinical trial populations. The use of real-
world data and observational study designs involving data
obtained from secondary data sources, including large
population-level data sets, is increasing. Analyzing how
patient characteristics and outcomes are similar or differ-
ent to interventional controlled trials is pivotal to better
understand and interpret both the data obtained from
interventional controlled trials and those from observa-
tional data sources.
To examine survival outcomes in patients with HER2-
positive advanced breast cancer in a comprehensive way,
we will conduct a systematic literature review and meta-
analysis. Our study will systematically identify and re-
view available published data from phase II and III inter-
ventional clinical trials and observational studies that
reported survival outcomes in patients with HER2-
positive advanced breast cancer from 1987, when HER2-
overexpressing breast cancer was identified as a distinct
phenotype, to the present. Here, we describe the proto-
col for this systematic review and meta-analysis.
Objectives
We will systematically evaluate clinical outcomes over
time in patients with HER2-positive advanced breast
cancer from both interventional clinical trials and obser-
vational studies and compare patient characteristics,
study characteristics, and outcomes within and between
these study design types.
Methods/Design
Study registration
This protocol has been registered with the international
prospective register of systematic reviews (PROSPERO) as
number CRD42014014345 (http://www.crd.york.ac.uk/
PROSPERO/display_record.asp?ID=CRD42014014345).
The systematic review protocol has been designed, con-
ducted, and reported by using the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines, as detailed in Additional file 1, and
the Meta-analysis of Observational Studies in Epidemi-
ology (MOOSE) reporting guidelines [21, 22].
Eligibility criteria
Eligible studies will meet the following criteria:
 Population: Adults with HER2-positive advanced
breast cancer (i.e., HER2-positive MBC or LABC)
identified prior to receipt of the first targeted or che-
motherapeutic agent for advanced breast cancer.
HER2-positive status is defined by each publication.
Mixed populations in which some patients had
HER2-positive MBC and others had LABC were
permitted. When tumor, node, metastasis (TNM)
status was provided, it was used to further evaluate
the study population for inclusion. The TNM classi-
fications of each subgroup are shown in Additional
file 2. Only those studies with at least 15 patients
with HER2-positive advanced breast cancer will be
used for the final analysis.
 Intervention/comparator: Any (e.g., surgery,
chemotherapy, hormonal therapy, radiation therapy,
or no intervention).
 Outcomes: OS and PFS.
o For both interventional controlled trials and
observational studies, eligible studies defined OS
as the time from the initiation of first-line treat-
ment in the advanced setting or as the time from
diagnosis of advanced breast cancer until death
from any cause.
o Eligible interventional controlled trials defined
PFS as the time from randomization until
objective tumor progression or death [23]. Patient
deaths are assumed to be randomly related to
tumor progression for the purpose of calculating
PFS. Eligible observational studies define PFS as
the time from the initiation of first-line treatment
or diagnosis of advanced breast cancer until
objective tumor progression or death.
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 Time of follow-up: At least 1 year.
 Study design: Randomized or quasi-randomized con-
trolled trials (i.e., interventional controlled trials)
and observational studies identified in the published
literature from 1 January 1987 to 5 September 2014.
Interventional controlled trials will be limited to
phase II/III clinical trials.
Outcomes of interest
Primary outcome:
 The primary outcome of interest is OS in patients
with HER2-positive advanced breast cancer, which
will be evaluated both overall and separately for




 Safety: The proportion of patients experiencing
adverse events and serious adverse events, the types
of adverse events reported, and the proportion of
patients experiencing adverse events of particular
interest as reported in prior studies (e.g., cardiac
toxicity [24]).
 Response rates (when available).
 Comparative assessment of study characteristics.
Search strategy for the identification of studies and
methods of review
We will conduct a systematic search of Medline,
EMBASE, and Cochrane Central Register of Controlled
Trials to identify relevant studies published between 1
January 1987 and 5 September 2014. EMBASE will be
used to identify conference abstracts. Abstracts with a
publication date within 3 years from the data cutoff
(i.e., 5 September 2014) are eligible for inclusion. The
search will be updated 1 month prior to the first sub-
mission of any manuscript based on these data. The
search terms in each of the bibliographic databases are
detailed in Additional file 3. The search will be limited
to humans and to English language abstracts. Dupli-
cates will be removed, and two investigators will assess
the abstracts independently by applying the inclusion/
exclusion codes. These codes are outlined in Additional
file 4. The kappa statistic will be used to calculate
agreement between the two investigators [25, 26]. Ab-
stracts that are rated discordantly will be reconciled
through discussion by the two independent raters and,
if needed, adjudicated by a third investigator. The full-
text versions of all abstracts that are rated as potentially
eligible by both investigators will be obtained to per-
form in-depth evaluations using inclusion/exclusion
codes, as shown in Additional file 5. The final inclu-
sion/exclusion status of each article will be summarized
and presented in a PRISMA flow chart [21].
Data extraction
Data extraction will be performed using a standard-
ized data extraction tool developed for this study by
the study team. Two independent reviewers with ad-
vanced clinical and methodologic expertise will ex-
tract data from each publication or congress abstract
meeting inclusion criteria across the following do-
mains: study characteristics, patient demographic and
clinical characteristics, treatment/intervention, survival
outcomes, safety events, and methodologic character-
istics. Discrepancies in the coding of data will be re-
solved by the two independent reviewers in order to
reach 100 % agreement, and if needed, a third study
investigator will adjudicate.
Study variables
We will extract the following data:
 Study characteristics: Author names, year of
publication, study setting, sponsorship of study, type
of study design, year of start of study enrollment or
observation, year of enrollment end or end of
observational period, maximum follow-up time, me-
dian follow-up time, and types of intervention re-
ported (e.g., pharmacologic, surgical, radiation,
none).
 Population characteristics: Treatment/intervention,
number of participants enrolled in the study, age of
study participants, race/ethnicity, Eastern
Cooperative Oncology Group performance status,
type of HER2 test and result (cutoff ), HER2
assessment at local or central laboratory, number
and proportion of patients with MBC and LABC,
type of disease (de novo or recurrent), adjuvant
treatment status, median disease-free interval, prior
adjuvant therapies (including HER2-targeted ther-
apy, chemotherapy, hormonal therapy, surgery, and
radiologic therapy), hormone receptor status, sites of
metastases (e.g., visceral, central nervous system,
other), and proportion of patients who dropped out
or who were lost to follow-up.
 Efficacy/effectiveness outcome variables: Number of
deaths, median OS, median PFS, and 95 %
confidence intervals, as well as event rates and
numbers at risk at 1-, 2-, and 5-year intervals. Data
from trial arms will not be excluded based on treat-
ment/intervention type or lack of active treatment/
intervention.
 Safety outcome variables: Proportion of patients
experiencing adverse events and serious adverse
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events, types of adverse events reported, and
proportion of patients experiencing adverse events
of particular interest as reported in prior studies
(e.g., cardiac toxicity [24]).
Assessment of methodological quality
We will assess the methodological quality and potential
bias in both interventional controlled trials and observa-
tional studies, using a structured measure of methodo-
logical quality developed and validated by Wao et al.
[27]. This measure uses a checklist derived from relevant
elements of existing evidence-based tools that include
the Quality in Prognosis Studies tool [28], the Evidence-
Based Medicine Group criteria for prognostic studies
[29], the Newcastle-Ottawa Quality Assessment Scale
[30], the Cochrane Collaboration risk of bias criteria
[31], and other studies [32, 33]. The Wao et al. measure
assesses potential bias in four domains: (1) participation
bias (i.e., How well does the study sample represent the
general population of interest?); (2) attrition bias (i.e., Is
attrition balanced across outcomes or characteristics of
interest?); (3) outcome measurement (i.e., Is the out-
come of interest measured appropriately?); and (4) data
analysis and reporting (i.e., Are the methods used opti-
mal?). The checklist is comprised of 11 items for cohort
studies and 14 items for randomized controlled trials.
Each study is evaluated for each item and is assigned 1
point for each criterion that is adequately addressed.
The overall methodological quality is determined by
examining the proportion of relevant criteria fulfilled for
studies within each design type (observational cohort,
randomized controlled trial).
To ensure a thorough assessment of methodological
quality in all included studies, we will employ further as-
sessments, as described below.
Methodological quality of interventional controlled tri-
als: We will assess concealment of allocation, determin-
ation of HER2 status at a central laboratory,
independent assessment of PFS, and the inclusion of
participants in the analysis according to the intent-to-
treat principle. Concealment of allocation will be consid-
ered adequate if the investigators responsible for the se-
lection of patients did not know prior to allocation
which treatment was next in line (e.g., central
randomization and sealed, opaque, sequentially num-
bered assignment envelopes). Any procedures based on
predictable generation of allocation sequences and po-
tentially transparent attempts to conceal allocation, such
as assignment envelopes that were not opaque or not
sealed, will be considered inadequate for randomized
controlled trials [34]. The analysis will be considered to
be according to the intent-to-treat principle if all pa-
tients were analyzed in the group to which they were
originally assigned [35].
Methodological quality of observational studies: Due
to inherent biases in observational designs, we will
measure multiple methodological characteristics within
each level. For cohort studies, we will include quality
characteristics that will assess biases due to design, rep-
resentativeness, comparability of groups, exposure, and
outcome measure and attrition.
 Study design: We will note the presence or absence
of comparison between at least two groups to assess
the effect/association of an exposure and an
outcome. We will also record whether exposure and
outcome were registered concurrently (retrospective
or prospective data collection; follow-up may be ac-
tive or retrospective with no prospective assessment
in a retrospective study).
 Representativeness: We will define this by the type
of study inclusion (i.e., consecutive or random
inclusion), criteria for justified exclusion of
participants for analysis, and whether the results are
generalizable (using Newcastle-Ottawa Scale) [36].
 Comparability: When there are two or more
exposure groups, comparability will be determined
by applying inclusion and/or exclusion criteria
equally to all groups and inclusion of all enrolled
patients in the analysis (analogous to the intent-to-
treat principle used in randomized trials). Mainten-
ance of comparability throughout the study will be
assessed by whether the length of follow-up was
similar between the groups [37].
 Biases in outcome measurement: We will assess
this by using an explicit definition of outcome
and by considering potential confounders in the
study and objective assessment using uniform
methods [38].
 Attrition: The effects of attrition will be assessed by
reviewing dropout rates in the groups and,
particularly, differential rates of attrition by
participant characteristics [37, 39, 40].
For both interventional controlled trials and observa-
tional studies, we will also include study size, balance
in the size of treatment/intervention groups, and pri-
mary funding source. Studies will be considered to have
balanced sizes of treatment/intervention groups if the
difference in the number of patients between groups
was less than fourfold. Studies will be identified as “suf-
ficient” if they included at least 15 patients in each
treatment/intervention group and more than 50 pa-
tients overall. The funding information extracted will
include setting (academic or not academic), industry
sponsorship (fully industry-sponsored, industry-
supported, or none), and any further details available
on the role of the sponsor in the conduct of the trial
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(e.g., extent of industry involvement in the study, re-
gardless of funding), as applicable.
Data analysis
Aggregate data will be used to summarize time trends in
OS and PFS for interventional controlled trials and ob-
servational studies. Individual study characteristics will
be described and summarized separately.
The outcome data will be analyzed using random ef-
fects meta-analysis [41]. Random effects meta-regression
models will be used to examine whether survival times
are affected by type of study, time era, treatment/inter-
vention (e.g., pharmacologic, surgical, radiation, none),
size of study, funding source, demographic characteris-
tics, clinical characteristics (e.g., hormone receptor sta-
tus), world region, post-progression therapy, and
relevant methodological quality parameters.
A cumulative meta-analysis will be performed to assess
the potential shift in outcome values over time. A cumu-
lative meta-analysis will be performed regardless of type
of treatment/intervention (including none), followed by
a subanalysis restricted by type of treatment/intervention
[38]. We will use meta-regression to perform stratified
analyses to establish the effect of the source of funding,
whether or not analyses had been adjusted for relevant
covariates, size of the study, and appropriate methodo-
logical characteristics.
For all meta-analyses, we will calculate the I2 statistic
to calculate the amount of variation across studies that
is attributable to heterogeneity rather than random vari-
ation [42]. We will construct funnel plots by plotting the
natural logarithm of the relative risk of individual trials
on the x-axis against their standard error on the y-axis.
We will enhance funnel plots by including contours div-
iding the plot into areas of significance with a two sided
P < 0.05 and areas of nonsignificance with a P ≥ 0.05
[43]. If studies appear to be missing in areas of nonsigni-
ficance, this will suggest the presence of bias. We will
then assess funnel plot asymmetry with regression tests,
a weighted linear regression of the natural logarithm of
risk ratios on their standard errors [44]. All analyses will
be performed using STATA 13.1 (Stata, College Station,
TX, USA).
Role of the study sponsor
This work represents a collaboration between the au-
thors, who are a group of academic clinicians and re-
searchers and representatives of the sponsor, Genentech.
All authors participated in the development of the study
design, drafting this article, and the decision to submit
this protocol for publication. When the study described
herein is conducted, data will be collected and analyzed
by all authors, who will have primary responsibility for
the completeness and accuracy of the data and analyses.
While Genentech is sponsoring the study, the authors
have primary responsibility for the data analysis and
publication-related decisions. The authors intend to
publish the results of their analysis and will make the
final decision to submit the work for publication.
Discussion
Characterizing the changes in survival outcomes over time
in patients with HER2-positive advanced breast cancer
will serve several purposes. First, this research may iden-
tify the extent to which changes in patient care have been
associated with improvements in patient survival. Add-
itionally, by including data from interventional controlled
trials and observational studies, we hope to provide insight
into how survival outcomes from these two different types
of studies may differ. Results from interventional con-
trolled trials provide an important assessment of the effi-
cacy and safety of interventions. Observational studies
provide additional insight into the effectiveness of treat-
ments and other interventions in the setting of real-world
patients, providers, and healthcare systems as they ap-
proximate this setting more closely than do interventional
controlled trials. Current accurate assessments of OS can
also inform clinical trial designs, as the result of a longer
OS duration would necessitate trial designs with larger
sample sizes and longer follow-up times. Finally, this study
may contribute to the state of research knowledge about
the characterization of HER2-positive advanced breast
cancer over time by providing important historical and
clinical context to current treatment approaches and out-
comes for patients.
The inherent biases within different types of study de-
signs present multiple challenges in meta-analyses of ob-
servational studies [45]. To help address the biases
associated with observational studies, we will list poten-
tial biases so that the data can be interpreted in this con-
text. We will also quantify the variation in outcomes
across studies to identify potential outliers and deter-
mine if study design elements contributed to the aber-
rant data.
The selection of OS as the primary outcome of interest
is a strength of our study. OS, when measured in intent-
to-treat populations with large sample sizes, is described
as the most reliable end point in oncology studies, least
subject to bias in end point measurement, and often the
preferred end point since blinding is not essential [23].
Assessment of OS is best performed using interventional
controlled trials, minimizing biases by providing a direct
outcome comparison group [23]. However, PFS is a
tumor assessment outcome that does not require a large
sample size, is censored at either tumor progression or
death, and requires objective and quantitative assess-
ment [23]. The assessment of both OS and PFS over
time among patients with HER2-positive advanced
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breast cancer may also provide insight into potential dif-
ferences observed in these two outcomes.
To our knowledge, this study will be the first compre-
hensive systematic review of outcomes in patients with
HER2-positive advanced breast cancer that evaluates
nearly 30 years of published data and includes both
interventional clinical trials and observational studies,
regardless of the presence or type of intervention. With
the addition of more diagnostic and therapeutic inter-
ventions for patients with HER2-positive advanced
breast cancer, it is important to patients, healthcare pro-
viders, and researchers to document and quantify
current and evolving trends in outcomes. This is particu-
larly important in the advanced setting, in which new
therapies have been recently approved and to more fully
understand the relationship between outcomes obtained
in an interventional controlled trial setting relative to
real-world clinical practice. It is thus essential that a
rigorous protocol be designed to pool and systematically
assess the available evidence.
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